|
Table 2: Targeted therapy agents. |
|||||||
|
Target agents |
Arrhythmia |
Cardio-myopathy |
Arterial vascular disease |
Pulmonar hypertension |
Systemic hypertension |
Pericardial disease |
Valvular heart disease |
|
Proteasome inhibitors (bortezomib, carfilzomib) |
|
+ |
+ |
|
+ |
|
|
|
HDAC inhibitors (vorinoztat) |
+ |
|
|
|
|
|
|
|
CDK4/CDK6 inhibitors (ribociclib) |
+ |
|
|
|
|
|
|
|
mTOR inhibitors (target of rapamycin) (everolimus) |
+ |
+ |
+ |
|
+ |
|
|
|
HER2 inhibitors (pertuzumab, trastuzumab) |
+ |
|
|
|
|
|
|
|
VEGF inhibitors (bevacizumab, sunitinib) |
|
+ |
+ |
|
+ |
|
|
|
BCR-ALB1 inhibitors (dasatinib, nilotinib, ponatinib) |
+ |
|
+ |
+ Dasatinib |
|
|
|
|
BTK inhibitors (ibrutinib) |
+ |
|
|
|
|
|
|
|
ALK inhibitors (alectinib, nilotinib, ponatinib) |
+ |
|
+ |
|
|
|
|
|
BRAK inhibitors (dabrafenib) |
+ |
+ |
|
|
|
|
|
|
MEK inhibitors (MAPK/ERK kinase) (binimetinib, cobimetinib, trametinib) |
+ |
+ |
|
+ |
|
|
|